Hepatitis B resistance in Iran

Emerging new medications in the treatment of HBV produces hope and promises for curing of HBV. Over the past decade, the development of oral nucleoside/nucleotide analogs (NAs) with favorable potencies and tolerabilities has led to substantial advances in chronic hepatitis B (CHB) therapy. The oral anti-HBV agents currently approved are lamivudine, adefovir dipivoxil , entecavir , telbivudine, clevudine, and tenofovir. Treatment algorithms have been developed to assist in identification of suitable candidates for treatment and to determine and initiate appropriate treatment. In this review the problem of drug resistance in the course of chronic hepatitis B treatment are discussed in detail from both aspects of clinical and genetics.